Manufacturing issues prompt FDA to reject Hengrui-Elevar filings for third time

An inspection of a facility making Elevar’s rivoceranib uncovered deficiencies, leading the FDA to reject a combination therapy that includes the drug. The rebuff is the third strike for the partners…